# NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System

Study · id `cardio:ct-nct07018596` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07018596](<https://clinicaltrials.gov/study/NCT07018596>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07018596

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 215 participants.

## Technical summary

Registry record NCT07018596. Allocation not applicable; no masking; primary purpose treatment. Start 2026-04-06 (actual); primary completion 2026-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 215 participants (planned count; ClinicalTrials.gov record NCT07018596, source copy `cardio:ctgov-nct07018596-2026-05-06`, retrieved 2026-10-26)
- Started: 2026-04-06 (actual) (ClinicalTrials.gov record NCT07018596, source copy `cardio:ctgov-nct07018596-2026-05-06`, retrieved 2026-10-26)
- Primary completion: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07018596, source copy `cardio:ctgov-nct07018596-2026-05-06`, retrieved 2026-10-26)
- Completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT07018596, source copy `cardio:ctgov-nct07018596-2026-05-06`, retrieved 2026-10-26)
- Countries: Czechia (ClinicalTrials.gov record NCT07018596, source copy `cardio:ctgov-nct07018596-2026-05-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07018596-2026-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System
- Acronym: NANOPULSE-AF
- Condition: Atrial Fibrillation Paroxysmal
- Condition: Cardiac Ablation
- Condition: Cardiac Arrhythmia
- Intervention (Device): CellFX nsPFA Cardiac Catheter System
- Lead sponsor: Pulse Biosciences, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: 03341638531e766d83c987642e528d69ab651960a25ec70a7e446b7b3041818a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
